SCHEMBL6501170

SCHEMBL6501170

O=CC(c1cccnc1)c1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.46
KCNA5 P22460 2/20 0.44
CYP11B1 P15538 1/20 0.44
TRPM8 Q7Z2W7 2/20 0.43
CYP1A1 P04798 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP1B1 Q16678 1/20 0.42
NFE2L2 Q16236 1/20 0.42
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PKM P14618 1/20 0.40
CFTR P13569 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9729576 0.85 ACP3 (0.46) CYP1A2SLC6A2SLC6A4ALDH1A1MEN1
SCHEMBL3907301 0.84 CYP19A1 (0.41) CYP19A1CYP11B1CYP1A2CYP3A4CYP2D6
SCHEMBL6503338 0.84 CYP19A1 (0.62) CYP19A1CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL3903975 0.81 CYP11B1 (0.44) CYP19A1CYP11B1SLC6A2SLC6A4SLC6A3
SCHEMBL3652018 0.81 CYP19A1 (0.46) CYP19A1KCNA5CYP3A4SLC6A2SLC6A4
Bromide SCHEMBL11274115 0.80 KCNA5 (0.41) CYP19A1KCNA5CYP11B1CYP1A1CYP1A2
SCHEMBL1515745 0.80 ACP3 (0.50) TRPM8ALDH1A1MEN1KMT2ANPC1
SCHEMBL360712 0.80 CFTR (0.57) CYP19A1KCNA5CYP11B1SLC6A2SLC6A4
SCHEMBL21778081 0.78 ACP3 (0.41) CYP1A2ALDH1A1MEN1KMT2AOPRM1
SCHEMBL11152058 0.78 ACP3 (0.41) CYP1A2ALDH1A1MEN1KMT2AOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 CYP19A1 2827/4885KCNA5 3736/4885CYP11B1 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.